Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | DHCR7 | Q9UBM7 | 3/20 | 0.38 |
| ▸ | EBP | Q15125 | 2/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24854051 | 0.88 | KDM4E (0.33) | KDM4EPOLBMEN1KMT2ADHCR7 | |
| SCHEMBL24854055 | 0.88 | KDM4E (0.33) | KDM4EPOLBMEN1KMT2ADHCR7 | |
| SCHEMBL681110 | 0.86 | PHGDH (0.36) | KDM4EPOLBMEN1KMT2AHTT | |
| SCHEMBL11916119 | 0.84 | SIGMAR1 (0.37) | KDM4EMEN1KMT2AALDH1A1ALOX15 | |
| SCHEMBL117945 | 0.84 | SIGMAR1 (0.41) | MEN1KMT2ASIGMAR1 | |
| Ammonia Solution, Strong SCHEMBL29214441 | 0.84 | PHGDH (0.34) | MEN1KMT2AHTTALDH1A1SIGMAR1 | |
| SCHEMBL24854481 | 0.83 | KDM4E (0.35) | KDM4EPOLBMEN1KMT2ADHCR7 | |
| SCHEMBL23717945 | 0.83 | — | — | |
| SCHEMBL16254537 | 0.83 | KDM4E (0.43) | KDM4EPOLBMEN1KMT2AALDH1A1 | |
| SCHEMBL15804607 | 0.83 | SIGMAR1 (0.31) | SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200048288-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-02-13 | — | — | US | disclosed |
| US-9873709-B2 | Triazolopyridine compounds, compositions and methods of use thereof | GENENTECH, INC. (US) | 2018-01-23 | — | — | US | disclosed |
| US-9873709-B2 | Triazolopyridine compounds, compositions and methods of use thereof | GENENTECH, INC. (US) | 2018-01-23 | — | — | US | disclosed |
| US-20170226132-A1 | TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-08-10 | — | — | US | disclosed |
| US-20170226132-A1 | TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-08-10 | — | — | US | disclosed |
| US-20170218000-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | ARIAD PHARMACEUTICALS, INC. | 2017-08-03 | — | — | US | disclosed |
| US-20160376297-A1 | Phosphorous Derivatives as Kinase Inhibitors | ARIAD PHARMA INC (US) | 2016-12-29 | — | — | US | disclosed |
| US-20160185780-A1 | TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2016-06-30 | — | — | US | disclosed |
| US-9273077-B2 | Phosphorus derivatives as kinase inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2016-03-01 | — | — | US | disclosed |
| US-20150225436-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | ARIAD PHARMACEUTICALS, INC. (US) | 2015-08-13 | — | — | US | disclosed |
| US-20130225527-A1 | Phosphorus Derivatives as Kinase Inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2013-08-29 | — | — | US | disclosed |
| US-20130225528-A1 | Phosphorus Derivatives as Kinase Inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2013-08-29 | — | — | US | disclosed |
| US-20120202776-A1 | PHOSPHORUS DERIVATIVES AS KINASE INHIBITORS | ARIAD PHARMACEUTICALS, INC. (US) | 2012-08-09 | — | — | US | disclosed |
| US-20120202776-A1 | PHOSPHORUS DERIVATIVES AS KINASE INHIBITORS | ARIAD PHARMACEUTICALS, INC. (US) | 2012-08-09 | — | — | US | disclosed |
| US-20120088768-A1 | PINANE-SUBSTITUTED PYRIMIDINEDIAMINE DERIVATIVES USEFUL AS AXL INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2012-04-12 | — | — | US | disclosed |
| US-8097630-B2 | Pinane-substituted pyrimidinediamine derivatives derivatives and pharmaceutical compositions containing the dthe activity of the receptor protein tyrosine kinase Axl. Methods of using erivatives are disclosed as being useful in inhibiting activity of enzyme | RIGEL PHARMACEUTICALS, INC. (US) | 2012-01-17 | — | — | US | disclosed |
| US-8097630-B2 | Pinane-substituted pyrimidinediamine derivatives derivatives and pharmaceutical compositions containing the dthe activity of the receptor protein tyrosine kinase Axl. Methods of using erivatives are disclosed as being useful in inhibiting activity of enzyme | RIGEL PHARMACEUTICALS, INC. (US) | 2012-01-17 | — | — | US | disclosed |
| US-20110183938-A1 | 1,7-DIAZACARBAZOLES AND METHODS OF USE | GENENTECH, INC. (US) | 2011-07-28 | — | — | US | disclosed |
| US-20080153815-A1 | PINANE-SUBSTITUTED PYRIMIDINEDIAMINE DERIVATIVES USEFUL AS AXL INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2008-06-26 | — | — | US | disclosed |
| US-20080153815-A1 | PINANE-SUBSTITUTED PYRIMIDINEDIAMINE DERIVATIVES USEFUL AS AXL INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2008-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160185780-A1 | TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | ABL1, JAK2, JAK1 | KDM4E 1708/4885POLB 2553/4885MEN1 2118/4885 |
| US-20170218000-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | MAP3K6, PIK3CA, MAP3K20 | KDM4E 1164/4885POLB 2336/4885MEN1 826/4885 |
| US-20120088768-A1 | PINANE-SUBSTITUTED PYRIMIDINEDIAMINE DERIVATIVES USEFUL AS AXL INHIBITORS | AXL, TYRO3, ERBB2 | KDM4E 4211/4885POLB 2466/4885MEN1 4368/4885 |
| US-20150225436-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | MAP3K6, PIK3CA, MAP3K20 | KDM4E 1122/4885POLB 2638/4885MEN1 1028/4885 |
| US-20110183938-A1 | 1,7-DIAZACARBAZOLES AND METHODS OF USE | CHEK1, CHEK2, BUB1B | KDM4E 1673/4885POLB 187/4885MEN1 738/4885 |
| US-20120202776-A1 | PHOSPHORUS DERIVATIVES AS KINASE INHIBITORS | PHKA1, PIK3CA, PHKA2 | KDM4E 1650/4885POLB 2380/4885MEN1 1214/4885 |
| US-20160376297-A1 | Phosphorous Derivatives as Kinase Inhibitors | MAP3K6, PIK3CA, MAP3K20 | KDM4E 1122/4885POLB 2638/4885MEN1 1028/4885 |
| US-20130225527-A1 | Phosphorus Derivatives as Kinase Inhibitors | PHKA1, PIK3CA, PHKA2 | KDM4E 1527/4885POLB 2246/4885MEN1 1313/4885 |
| US-20130225528-A1 | Phosphorus Derivatives as Kinase Inhibitors | PHKA1, PIK3CA, PHKA2 | KDM4E 1527/4885POLB 2246/4885MEN1 1313/4885 |
| US-20200048288-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | MAP3K6, PIK3CA, MAP3K20 | KDM4E 1164/4885POLB 2336/4885MEN1 826/4885 |
| US-20080153815-A1 | PINANE-SUBSTITUTED PYRIMIDINEDIAMINE DERIVATIVES USEFUL AS AXL INHIBITORS | AXL, TYRO3, MERTK | KDM4E 4278/4885POLB 2453/4885MEN1 4367/4885 |
| US-20170226132-A1 | TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | ABL1, JAK2, JAK1 | KDM4E 1708/4885POLB 2553/4885MEN1 2118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.